ArticlePituitary2026
Prolactin measurements in a real-life setting: a population-based cohort study.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHyperprolactinemia is mainly due to pituitary disorders including prolactinomas but other causes including adverse drug reactions exist. This study aimed to assess the frequency and pattern of serum prolactin measurements in a population-wide cohort in Central Region Denmark (1.32 mill inhabitants) from 2011 to 2022.
methodsUsing the Central Denmark Region’s data warehouse, we identified all individuals who had at least one prolactin measurement in the study period.
resultsWe identified 84,145 individuals who had at least one measurement of prolactin. Among these, 17,008 (20.3%) had at least one measurement of elevated prolactin corresponding to an incidence of 107 per 100.000 person-years. Hyperprolactinemia, defined by at least two elevated prolactin concentrations, occurred in 5,810 individuals (73.9% female), with an incidence of 36.7 per 100.000 person-years. Only 12.7% of individuals with hyperprolactinemia were treated with dopamine agonists.
conclusionWe found a substantial number of repeated prolactin measurements, many of which did not seem to lead to clinical action. The findings support the need for guidelines for management of hyperprolactinemia to ensure proper utilization of health resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.